# 10x Genomics, Inc.: overview

TXG · Nasdaq · CIK 1770787 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/txg.md) · [Financials](/companies/txg/financials.md) · [Filings](/companies/txg/filings.md) · [Insiders](/companies/txg/insiders.md)

Latest reported revenue: [$151.0m](/filings/0001628280-26-054491.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054491).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [152](/filings/0001628280-25-050332.md) | [165 d](/filings/0001628280-26-007822.md) | [155](/filings/0001628280-26-032388.md) | [173](/filings/0001628280-26-054491.md) | [149](/filings/0001628280-25-050332.md) | [166 d](/filings/0001628280-26-007822.md) | [151](/filings/0001628280-26-032388.md) | [151](/filings/0001628280-26-054491.md) |
| Gross margin | % | [70.2%](/filings/0001628280-25-050332.md) | [67.2% d](/filings/0001628280-26-007822.md) | [68.1%](/filings/0001628280-26-032388.md) | [72.3%](/filings/0001628280-26-054491.md) | [67.3%](/filings/0001628280-25-050332.md) | [68.1% d](/filings/0001628280-26-007822.md) | [70.4%](/filings/0001628280-26-032388.md) | [74.5%](/filings/0001628280-26-054491.md) |
| Operating margin | % | [(27.4%)](/filings/0001628280-25-050332.md) | [(30.2%) d](/filings/0001628280-26-007822.md) | [(25.4%)](/filings/0001628280-26-032388.md) | [17.4%](/filings/0001628280-26-054491.md) | [(21.6%)](/filings/0001628280-25-050332.md) | [(11.8%) d](/filings/0001628280-26-007822.md) | [(11.3%)](/filings/0001628280-26-032388.md) | [(12.9%)](/filings/0001628280-26-054491.md) |
| Net margin | % | [(23.6%)](/filings/0001628280-25-050332.md) | [(29.7%) d](/filings/0001628280-26-007822.md) | [(22.2%)](/filings/0001628280-26-054491.md) | [20.0%](/filings/0001628280-26-054491.md) | [(18.4%)](/filings/0001628280-25-050332.md) | [(9.8%) d](/filings/0001628280-26-007822.md) | [(8.9%)](/filings/0001628280-26-054491.md) | [(11.9%)](/filings/0001628280-26-054491.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0001628280-25-050332.md) | not reported | [(0.28)](/filings/0001628280-26-032388.md) | [0.28](/filings/0001628280-26-054491.md) | [(0.22)](/filings/0001628280-25-050332.md) | not reported | [(0.10)](/filings/0001628280-26-032388.md) | [(0.14)](/filings/0001628280-26-054491.md) |
| Free cash flow | $m | [17.8 d](/filings/0001628280-25-050332.md) | [(9.5) d](/filings/0001628280-26-007822.md) | [32.5](/filings/0001628280-26-032388.md) | [16.1 d](/filings/0001628280-26-054491.md) | [42.5 d](/filings/0001628280-25-050332.md) | [39.0 d](/filings/0001628280-26-007822.md) | [24.5](/filings/0001628280-26-032388.md) | [15.4 d](/filings/0001628280-26-054491.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [490](/filings/0001770787-24-000017.md) | [516](/filings/0001770787-25-000013.md) | [619](/filings/0001628280-26-007822.md) | [611](/filings/0001628280-26-007822.md) | [643](/filings/0001628280-26-007822.md) |
| Gross margin | % | [84.9%](/filings/0001770787-24-000017.md) | [76.7%](/filings/0001770787-25-000013.md) | [66.2%](/filings/0001628280-26-007822.md) | [67.9%](/filings/0001628280-26-007822.md) | [69.1%](/filings/0001628280-26-007822.md) |
| Operating margin | % | [(10.7%)](/filings/0001770787-24-000017.md) | [(32.5%)](/filings/0001770787-25-000013.md) | [(42.9%)](/filings/0001628280-26-007822.md) | [(31.9%)](/filings/0001628280-26-007822.md) | [(9.5%)](/filings/0001628280-26-007822.md) |
| Net margin | % | [(11.9%)](/filings/0001770787-24-000017.md) | [(32.1%)](/filings/0001770787-25-000013.md) | [(41.2%)](/filings/0001628280-26-007822.md) | [(29.9%)](/filings/0001628280-26-007822.md) | [(6.8%)](/filings/0001628280-26-007822.md) |
| Diluted EPS | $ per share | [(0.53)](/filings/0001770787-24-000017.md) | [(1.46)](/filings/0001770787-25-000013.md) | [(2.18)](/filings/0001628280-26-007822.md) | [(1.52)](/filings/0001628280-26-007822.md) | [(0.35)](/filings/0001628280-26-007822.md) |
| Free cash flow | $m | [(123)](/filings/0001770787-24-000017.md) | [(165)](/filings/0001770787-25-000013.md) | [(63.8)](/filings/0001628280-26-007822.md) | [(5.7)](/filings/0001628280-26-007822.md) | [130](/filings/0001628280-26-007822.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/txg/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $675.9m | 17,629,266 |  | Reduced −111,706 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $414.2m | 10,804,070 |  | Added +724,157 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $383.5m | 10,003,057 |  | Reduced −1,714,260 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $267.7m | 6,982,492 |  | Added +69,556 |
| [Quantinno Capital Management LP](/funds/1759654.md) | 2026-06-30 | $209.7m | 5,469,698 |  | Added +57,937 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $194.9m | 5,082,594 |  | Reduced −186,992 |
| [Sumitomo Mitsui Trust Group, Inc.](/funds/1475365.md) | 2026-06-30 | $160.8m | 4,194,627 |  | Reduced −915,587 |
| [Amova Asset Management Americas, Inc.](/funds/1480751.md) | 2026-06-30 | $160.7m | 4,192,517 |  | Reduced −911,661 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $128.5m | 3,351,911 |  | Added +695,558 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $120.7m | 3,148,859 |  | Reduced −822,941 |

## Recent filings

[All 684 filings](/companies/txg/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 21:31 ET | [10-Q](/filings/0001628280-26-054491.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054491 |
| 2026-08-06 | 20:03 ET | [8-K](/filings/0001628280-26-054273.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-054273 |
| 2026-06-08 | 20:46 ET | [8-K](/filings/0001628280-26-041651.md) | 5.07 Shareholder vote results | 0001628280-26-041651 |
| 2026-05-08 | 21:36 ET | [10-Q](/filings/0001628280-26-032388.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032388 |
| 2026-05-07 | 20:03 ET | [8-K](/filings/0001628280-26-032073.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-032073 |
| 2026-04-24 | 20:06 ET | [DEF 14A](/filings/0001628280-26-027201.md) | Proxy statement, period 2026-06-04 | 0001628280-26-027201 |
| 2026-02-13 | 22:38 ET | [10-K](/filings/0001628280-26-007822.md) | Annual report, period 2025-12-31 | 0001628280-26-007822 |
| 2026-02-12 | 21:09 ET | [8-K](/filings/0001628280-26-007673.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-007673 |
| 2026-01-12 | 20:52 ET | [8-K](/filings/0001628280-26-001808.md) | 2.02 Results of operations | 0001628280-26-001808 |
| 2025-11-14 | 23:41 ET | [8-K](/filings/0001628280-25-052154.md) | 5.02 Departure or appointment of officers or directors | 0001628280-25-052154 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-007822.md), filed Feb 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e3a49569-cd52-4b15-84f7-a44df5afd1a4)

## About the filer

- CIK: 1770787
- Tickers: TXG
- Exchange: Nasdaq
- SIC code: 3826 Laboratory Analytical Instruments
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.